138 related articles for article (PubMed ID: 8854074)
1. Tissue polypeptide-specific antigen in renal cell carcinoma.
Höbarth K; Hallas A; Kramer G; Aulitzky W; Gomahr A; Steiner G; Marberger M
Eur Urol; 1996; 30(1):89-95. PubMed ID: 8854074
[TBL] [Abstract][Full Text] [Related]
2. Tissue polypeptide specific antigen (TPS) as a tumor marker in renal cell carcinoma.
Chang CH; Wu HC; Yen RF; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(5):2949-50. PubMed ID: 12530023
[TBL] [Abstract][Full Text] [Related]
3. Circulating immune markers in advanced renal cell carcinoma during immunotherapy with interferon gamma.
Höbarth K; Hallas A; Steiner G; Gomahr A; Aulitzky W; Marberger M
Urol Res; 1996; 24(2):101-6. PubMed ID: 8740979
[TBL] [Abstract][Full Text] [Related]
4. Expression of cytokeratin-18-related tissue polypeptide-specific (TPS) antigen in Wilms tumor.
Rebhandl W; Handisurya A; Memaran N; Felberbauer FX; Aberle J; Paya K; Strobl B; Horcher E
Med Pediatr Oncol; 2001 Oct; 37(4):357-64. PubMed ID: 11568899
[TBL] [Abstract][Full Text] [Related]
5. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume.
Partin AW; Criley SR; Steiner MS; Hsieh K; Simons JW; Lumadue J; Carter HB; Marshall FF
Urology; 1995 Feb; 45(2):211-7. PubMed ID: 7855968
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancer.
Pujol JL; Cooper EH; Grenier J; Purves DA; Lehmann M; Ray P; Aouta MD; Bashir M; Godard P; Michel FB
Eur J Cancer; 1994; 30A(12):1768-74. PubMed ID: 7880603
[TBL] [Abstract][Full Text] [Related]
7. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3.
van Dalen A
Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693
[TBL] [Abstract][Full Text] [Related]
8. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B
Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
12. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
13. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH
Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
[TBL] [Abstract][Full Text] [Related]
15. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Terakawa T; Miyake H; Kusuda Y; Fujisawa M
Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
[TBL] [Abstract][Full Text] [Related]
16. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma.
Shabana A; Onsrud M
Tumour Biol; 1994; 15(6):361-7. PubMed ID: 7997808
[TBL] [Abstract][Full Text] [Related]
17. Preoperative high levels of serum vascular endothelial growth factor are a prognostic marker for poor outcome after surgical treatment of renal cell carcinoma.
Guðbrandsdottir G; Hjelle KM; Frugård J; Bostad L; Aarstad HJ; Beisland C
Scand J Urol; 2015; 49(5):388-94. PubMed ID: 25773545
[TBL] [Abstract][Full Text] [Related]
18. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker.
Väänänen T; Kallio J; Vuolteenaho K; Ojala A; Luukkaala T; Hämäläinen M; Tammela T; Kellokumpu-Lehtinen PL; Moilanen E
Scand J Urol; 2017 Oct; 51(5):367-372. PubMed ID: 28644702
[TBL] [Abstract][Full Text] [Related]
19. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma.
Sato K; Tsuchiya N; Sasaki R; Shimoda N; Satoh S; Ogawa O; Kato T
Jpn J Cancer Res; 1999 Aug; 90(8):874-9. PubMed ID: 10543260
[TBL] [Abstract][Full Text] [Related]
20. Serum basic fetoprotein in patients with renal cell carcinoma.
Gohji K; Ishii M; Nagata H; Matsumoto O; Kamidono S
Cancer; 1990 Mar; 65(6):1405-11. PubMed ID: 1689608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
